Loading...
01/11 04:26
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture: modest revenue growth and improved gross profit are overshadowed by consistent net losses and negative EBITDA. The Q&A reveals potential in waste receipts and PFAS technology, but management's vague responses on margins and project timelines raise concerns. The absence of a share repurchase program and international expansion risks further balance the outlook. Overall, the stock is likely to remain stable, with no strong catalysts for significant movement.
Total Revenue $13.9 million, up $302,000 or 2.2% year-over-year due to increased waste volumes in the Treatment segment.
Treatment Segment Revenue Increased by $477,000 or 5.5% year-over-year due to higher waste volumes received and processed, offset by lower pricing.
Service Segment Revenue Decreased by $175,000 year-over-year as new projects in 2025 mostly offset completed projects from Q1 of 2024.
Gross Profit $657,000 compared to a gross loss of $620,000 in Q1 of 2024, with the Treatment segment's gross profit increasing by $302,000 due to higher revenue and lower variable costs.
Service Segment Gross Profit Increased by $975,000 year-over-year due to lower variable costs and improved profitability of projects.
SG&A Costs $4 million, up $471,000 year-over-year due to higher labor costs, legal expenses, and marketing expenses.
Net Loss $3.6 million, consistent with last year's loss of $3.6 million, with loss per share improving from $0.26 to $0.19.
EBITDA Negative $3.3 million compared to negative $4 million last year.
Cash on Balance Sheet $25.7 million, down from $29 million at year-end.
Net Accounts Receivables Lower by $2.3 million due to improved collection of outstanding receivables.
Current Liabilities Down approximately $1.2 million due to decreased production costs and timing of vendor payments.
Waste Backlog $10.2 million, up from $7.9 million at year-end and consistent with $10.6 million a year ago.
Total Debt $2.3 million, primarily owed to PNC Bank.
Cash Used in Operating Activities $2 million for continuing operations.
Cash Used in Investing Activities $571,000 for continuing operations, primarily for capital expenditures.
Cash Used in Financing Activities $396,000, primarily for payments on loans and leases.
PFAS Program: The PFAS program has advanced with first commercial shipments from the federal government and system upgrades that integrate chemical recycling, reducing costs and improving efficiencies. The Gen 2 unit is on track for Q4 deployment, expanding processing capacity by at least three times.
International Waste Receipts: Improved activity with approximately $7 million worth of waste received from Canada, Mexico, and Germany, with more expected in May and June.
Federal Procurement Opportunities: The company is pursuing a robust pipeline of federal and commercial projects, including opportunities at West Valley and Hanford, with initial operations expected to begin in July.
Treatment Segment Improvement: The Treatment segment saw a backlog growth to over $10 million, a 30% increase from 2024, with revenue and gross profit improvements due to higher waste volumes and efficiency initiatives.
Cost Management: Disciplined indirect cost management is being maintained while supporting larger project opportunities expected later this year.
International Expansion: The company is expanding internationally through strategic partnerships, including the JRC Italy project, with treatment operations expected to start in late 2026.
Long-term Strategy: The company aims to diversify revenue through international expansion and strategic partnerships, focusing on engaging established generators of radioactive and hazardous waste.
Procurement Delays: Delays in procurement and project activity tied to the federal administration transition have negatively impacted revenue growth.
Federal Procurement Activity: Revenue in the Services segment decreased due to delays in federal procurement activity, particularly in early-stage projects.
Cost Management: Higher labor costs, particularly at the executive level, have contributed to increased SG&A costs.
Regulatory Challenges: The company is tracking legislative activity in multiple states regarding PFAS destruction, which could impact demand and operational strategies.
Competitive Pressures: The USS Enterprise decommissioning bid remains highly competitive, with an award expected around mid-year.
International Expansion Risks: The company is expanding internationally, which involves risks associated with regulatory compliance and market entry.
Economic Factors: Economic conditions may affect the company's ability to secure contracts and manage costs effectively.
Treatment Segment Improvement: The Treatment segment showed improvement with waste receipts increasing, contributing to a backlog of over $10 million, up approximately 30% from 2024.
PFAS Program Advancement: The PFAS program received first commercial shipments from the federal government, with upgrades to the system improving efficiencies. The Gen 2 unit is on track for Q4 deployment, expected to triple processing capacity.
DFLAW Program Support: The DFLAW program at Hanford is on schedule for an August 1 start, with potential for significant high-margin recurring revenue beginning in Q4.
International Expansion: Improved international waste receipts of approximately $7 million from Canada, Mexico, and Germany, with ongoing efforts to expand partnerships in Europe and Latin America.
Cost Management: Disciplined cost management is being applied while maintaining flexibility to support incoming contract activities.
Revenue Outlook: Stronger performance is anticipated in the second half of 2025, supported by a growing waste treatment backlog and improved visibility on federal procurement activities.
Key Growth Drivers: Outlook is supported by five key drivers: growing waste treatment backlog, DFLAW program ramp-up, PFAS technology advancement, and execution of large-scale domestic and international opportunities.
Financial Projections: The company expects to generate significant recurring revenue from the DFLAW program starting in Q4 and anticipates awards from DOE and DOD contracts in 2025.
Share Repurchase Program: None
The earnings call summary presents a mixed outlook. Financial performance and shareholder returns show improvement, but the guidance lacks clarity, especially regarding margins and partnerships. Q&A insights reveal uncertainties in PFAS progress and waste treatment margins, balanced by strong backlog and potential contracts. No clear catalyst for a strong price movement is evident, leading to a neutral sentiment.
The earnings call highlights a significant improvement in gross profit and a reduced net loss, indicating better financial performance. The increase in waste backlog and the anticipated start of the Hanford project provide strong growth prospects. Despite challenges in the Services segment and regulatory delays, the company's strategic initiatives, such as the PFAS program and Gen II deployment, are promising. The Q&A session reflects confidence in overcoming operational hurdles. Overall, the positive financial trajectory and growth initiatives suggest a positive stock price movement.
The earnings call presents a mixed picture: modest revenue growth and improved gross profit are overshadowed by consistent net losses and negative EBITDA. The Q&A reveals potential in waste receipts and PFAS technology, but management's vague responses on margins and project timelines raise concerns. The absence of a share repurchase program and international expansion risks further balance the outlook. Overall, the stock is likely to remain stable, with no strong catalysts for significant movement.
The earnings call highlighted modest revenue growth and improved profitability metrics, but persistent net losses and cash decline are concerns. The Q&A revealed increased waste receipts from Hanford, but management's vague responses on margins and budget impacts raise uncertainties. The absence of a shareholder return plan and international expansion risks further temper sentiment. Despite potential PFAS demand growth, competitive pressures and no new partnerships or guidance adjustments limit positive catalysts. Overall, the mixed financial performance and strategic outlook suggest a neutral stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
